

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – RESULTS FROM RETAIL COMPONENT OF ENTITLEMENT OFFER (ANREO)

- **Completion of Retail Entitlement Offer**

SYDNEY, Friday, 10 March 2023

Anagenics Limited (**Anagenics** or the **Company**) is pleased to advise the completion of the Retail Entitlement Offer (**REO**) under the ANREO (as originally announced on 14 February 2023).

Under the REO eligible shareholders were invited to apply for 1 New Share for every 1.3748 shares held on the Record Date at \$0.022 per New Share. Following the closure of the REO the Company received valid applications for 9,474,844 New Shares raising \$208,447 (before costs). Settlement of the REO New Shares is expected to occur on 10 March 2023 with the allotment of the REO New Shares expected to be no later than 13 March 2023 and with trading of REO New Shares expected to commence on the ASX on 14 March 2023.

Completion of the REO follows the completion of the institutional component of the ANREO (as announced to the ASX on 16 February 2023) which raised \$614,800 (before costs).

The ANREO was fully underwritten by Hancock & Gore Limited (ASX:HNG) (**Underwriter**) pursuant to an Underwriting Agreement, a summary of which is available in the Investor Presentation released to the ASX on 14 February 2023. Following the completion of the REO, there was a shortfall of 106,929,787 New Shares (**Shortfall Shares**) which will be subscribed for by the Underwriter. The Underwriter has now also entered into a sub-underwriting arrangement and for the purposes of the disclosure requirements of the ASX Listing Rules, Anagenics provides the following details of that sub-underwriting arrangement:

1. Sub-underwriting party: H&G High Conviction Limited;
2. Sub-underwriting commitment: up to 45,454,545 AN1 shares;
3. Sub-underwriting fee: 1.50% of the aggregate subscription price for the Shortfall Shares taken up by the sub-underwriter, payable by the Underwriter; and
4. The sub-underwriting arrangement has no termination provisions.

The Shortfall Shares will be issued upon receipt of cleared funds from the Underwriter and sub-underwriting party.

Approved for release by the Independent Board Committee of Anagenics Limited.

Matthew Dudek
CEO
+61 455 503 790
info@anagenics.com

ANAGENICS

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics' wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see www.anagenics.com and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.